the call is free, the quote is free, and there's no obligation to buy. call or go online now, so the next time there's a power outage, your home powers up. power your life with generac. call or go online to request your free quote today. welcome to "power lunch." courtney reagan and i am tyler mathisen. glad you could join us on this february 29. the rarest day on the calendar and we market as a rare disease day. it is officially such print a dray -- day to bring attention to the disorder but when you realize there are thousands of these diseases out there, they affect millions of families. we met the statistics are

staggering. we will talk to the head of the national organization for rare disorders about the scope of the problem but you might be surprised as i was. we will talk to the ceo of a company working in this area about the process for getting treatment approved and a look at some of the stocks involved in this opportunity to invest in companies working to treat or even cure these diseases. first, a check out the markets. the stocks are mixed following the latest on inflation we got this morning. we have the nasdaq composite up about 6/10 of a percent. the s&p 500 a pretense. nasdaq just about flak to the downside. les is bringing like santelli for more on the reaction to this morning's pce number. it was about what we had forecast but still hotter than what the fed wants to see. >> i would characterize the market response as mild relief that it was not a surprise forecast. we've had two or three in a row. they could come in hotter than anticipated.

this was at least on target. it was warm in the areas we have no more going to be steadily so, like a lot of services. a lot of prices on financial services. the market is not really doing much with that number. however, right before the report, we were looking at one third of a percent decline in the s&p 500 and we are now up a third of a percent. you went from a 4.7 down to about 462. it is not a huge swing. it does show you that we are checking off the box that the fed in inflation measure is not worse. it is down below 3% somewhere. >> mike, thanks very much. we want you to stay right there as we bring in the next guest to says the data does not matter that much for the fed has a physical problem, not a rates problem. keith fitzgerald is the principal of the fitzgerald group and what do you mean it has a fiscal problem? >> i would be happy to.

the government, take it or leave it, does not matter what aisle you are on, they have a spending problem. and they really have to struggle. they may take blood out of their left arm and putting them in the right arm the markets will address this. >> what does that leave us as an investor to do when you see inflation coming in, basically 2.8, a little higher than the fed would like to see your over a year. but it is nothing to be terribly learned about. what should i do with my money now?may raised an interesting point. time to take a deep breath, stick with what you know. that is the great companies, world class companies that put up great results, great numbers, regardless of what the fed actually thinks is going to do or what traders think the fed is going to do. >> let's talk about one of your picks, and let you make your thesis known on apple, which i think you think is a very good buy at these prices, in part because it has now jumped its

automobile operation and gone all in on a.i.. >> i see this as another job -- jobs when he introduced the iphone in 2007. this is a moment where you are going to see a pivot, something that is going to dramatically change the way the company is perceived. tim cook has been hinting at it. if you look behind the scenes, i think apple is a lot more involved in a.i. than the world understands. whatever happens in june, with the developer conference, i think it's going to take a lot of people by surprise. i think prices moving in sharply, to 75 a share. >> that's high where we sit right now, just above one 80. do you have a stake an apple? >> yes i, do i own it personally. my family does. and our firm continues to. >> got it. mike, when you look at a name like apple which has been an underperformer, we used to say as goes apple, so goes the rest of the market. that does not necessarily seem to be the case anymore.

after the announcement, knowing that they're walking away from the car, but potentially putting more firepower into a.i., four they have driven a lot of market growth. you can use it as this market sentiment marker. >> i would say it remains to be seen. there are periods of time when it is hard to remember, when apple went sideways, and the market was up, sometimes it is bellwether. -- first two months of this year is the market has answered some of the biggest criticisms thrown at it in 2024. one, it's way too reliant on massive growth stocks. you see apple falter, you see alphabet falter and the rest of the market is hanging in there and actually posting gains. with the stock market is overly dependent on soon -- rate cuts soon, and deep ones. we've had to revise that look to say no, we're not getting

that until june or july, and then not many this year. it's all because nominal growth has been good, earnings have come back, and they've made gestures broadening out. >> that's an appointed point that you made, mike. the idea that the market has been able to, against maybe the popular consensus, make progress even though interest rate cuts are not imminent. they're not coming in march apparently. they may not come in may, i think that's the next one, maybe not even until the latter half of the year. let's go to other stocks you like, that is chevron. what is your thesis there? >> well, again, i'm a big fan of keeping things really simple. this is a case where, you know, the backlash against ev, for one reason or another, whether it's pricing, availability, manufacture challenges, it doesn't matter what, we need dinosaur juice for a lot longer than we think. the company's cash efficient balance sheet, they return a huge amount of cash to

shareholders. they produce three, four, 5%, maybe more oil this year. high margin activity. 37 consecutive years of dividend. it's a solid holding that you can count on. >> keith, thank you very much. keith, mike, you as well. let's go to emily wilkins in washington on breaking news. will the government avoid a shutdown emily? >> hey tyler, well, congress is rushing to avoid a shutdown. it is now set to start on friday at midnight. it is looking good for being able to avoid that. the house just now getting the votes needed to go ahead and pass that stopgap measure, kicking the can down the road to march 8th. then to march 22nd for both pieces of government funding. the bill could now go to the senate, where it might be able to actually pass today. remember, you need all senators to agree to time limits if you want something to move quickly. that seems like it does have the potential to happen. at this point, congress is moving quickly to try to get the stopgap in place which means the real big question,

can they actually make these deadlines? after moving the goalposts yet again, can we actually see some full fiscal year spending bills by march 8th and march 22nd? lawmakers on the hill are confident but we have heard that before. so we're continuing to watch this closely. >> i was just going to say, it feels like a similar story, different day, different year. thank you very much, emily wilkins. let's get to the bond market reaction to the latest inflation rate. brook santelli joining us from the windy city. hi, brook. >> reporter: hi, we had a lot of numbers this morning. and, let's get some major highlights. year over year, pce core is something many were very anxious to monitor. how did it show up? well, as you look at this chart which starts in january of last year, we now have 12 consecutive months of lower year over year pc corps. you see the line moving down. now, here is one of the rubs. if you open the chart to pre covid, you can see that even though we have come down, we are still a ways from where we

were pre-covid. we are still on our way to target 2%, but we are not quite there yet. as a matter of fact, if you continue to look at all of the variables today, continuing claims is also a bit surprising. it came out over 1.9 million. we have not done that since mid november of last year. but, as you see on this chart, i went back to november of 2021. that is how close we are two levels going back that far. we definitely want to continue to monitor the slight increases we are starting to see in claims that have been well behaved, but we are now monitoring them with a fine tooth comb. here is a chart year to date of two year end tenure on one chart. there is several things i would like to point out. right now, we are basically at four 62 in a two-year. pre-the number releases, we are for 68. so we have a decent drop. but we are only down to. and if you consider that right

now we are now looking at a four 68 with pre number, but for -- before the 4:31 pre-on tens, now, that move on about eight base points. here's what i want to say. if you look at the all-time high for 2024, we are now ten basis points below that, but we are up 37 on the year. if you look at tens, right now, we are at six and 4:23. we are down nine when it comes to the high yield closes, but we are up 35 on the year. you get what i'm saying. we are hogging up to higher levels, even though the numbers were too many just perfect with respect to inflation. tyler? back to you. >> rick, let me get your forecasting hat on. as we sit there with the ten year in the four twentysomethings, is it your view that we are likelier to stay right around here in this higher part of the band then go back to where we were a couple

of months ago in the high threes? >> i absolutely do. i think that, based on the way it has acted for 2024 and those ratios i pointed out, i think it's actually more likely that we will be more in a range of four in a quarter than four and a half from anything under four and up to four and a quarter. >> rick, thank you very much. rick santelli reporting for us. in the meantime, coming up, from chile to mexico and all the way to your. of chinese car brands are exploding in popularity. we will look at why, next. plus, still to come on the program, an in-depth look at an issue that affects one in ten people in the u.s.. rare diseases and conditions. chances are, you know somebody afflicted. so on this rare disease day, we want to shine a spotlight on the people, the industry and treatments that are out there. and they may be coming. we will be right back.

rylee! from rylee's realty! hi! this listing sounds incredible. let's check it out. says here it gets plenty of light. and this must be the ocean view? of aruba? huh. this listing is misleading. well, when at&t says we give businesses get our best deal, on the iphone 15 pro made with titanium. we mean it. amazing. all my agents want it. says here...“inviting pool”. come on over! too inviting. only at&t gives businesses our best deals on any iphone. get iphone 15 pro on us. (♪♪)

municipal bonds don't usually get the media coverage the stock market does. in fact, most people don't find them all that exciting. but, if you're looking for the potential for consistent income that's federally tax-free. now is an excellent time to consider municipal bonds from hennion & walsh. if you have at least $10,000 to invest, call and talk with one of our bond specialists at 1-800-217-3217. we'll send you our exclusive bond guide, free with details about how bonds can be an important part of your portfolio. hennion & walsh has specialized in fixed income and growth solutions for 30 years, and offers high-quality municipal bonds from across the country. they provide the potential for regular income are federally tax-free and have historically low risk. call today to request your free bond guide. 1-800-217-3217. that's 1-800-217-3217.

welcome back to power lunch. china's v weighty path -- test became the world's biggest electric car maker. you won't find pyds on the streets in the u.s.. so we sent someone to santiago, chile, to find out why chinese brands are popular there. we knew very little about this car. >> you know, courtney, we're here in a mall in santiago. this is the byd dolphin. this is the smallest byd e.v.a. that is sold. it is the precursor to what will be coming out over the next year, which is the siegel, which is an even smaller one and is expected to be priced for $11,000. here in santiago, byd enter the market last year. what about tesla? they just enter the market earlier this month. in fact, we went to what you might call the tesla gallery. really more of a cube that had a model three in it.

people came by and took a look at. it you could go in and talk with representatives about potentially buying a tesla. in terms of south america, it is just starting to develop as an ev market. that is why tesla's first mark it down here is santiago, chile. although they expect to expand overtime. globally b sales, if you look at the numbers last year, let's be clear, we're talking about pure electric vehicles, not hybrids. it was just under 9.5 million, 11% of all the vehicles sold last year. and yes, last year, tesla was number one. selling 1.8 million. byd, number one -- two at 1.6 million. the person who runs the byd dealership here in chile believes that they will gradually but steadily increase sales here. -- the reaction has been fantastic because with the new technology, the electric vehicle course -- the people are arriving to the stores, they are going to our new store to try to understand how this

new technology -- and they have been listening about byd. >> reporter: if you take a look at shares of byd n tesla, they have roughly traded in tandem with each other. not a surprise. you tend to see this, two ev companies tend to trade in the same way over a period of time. by the way, byd did outsell tesla in the fourth quarter. you will hear someone say, pyds number one worldwide. well, we can look at the sales on an annual basis. last year, tesla was still number one. will that change this year? likely. because byd is growing sales dramatically in china, and as we, know tesla has been much more judicious and has had to deal with the price wars going on in china. now they're competing here in chile and we will see it increasingly in other parts of south america as well. back to you. >> i was just going to say, phil, i'm struck by the prices. the byd car is significantly less expensive than tesla.

i'm surprised they have only sold 1.6 million of them. >> reporter: well, they sell a lot of hybrids. if you add in pyds hybrid sales, which are even greater, than they are pure electric vehicle sales, it's over 3 million. but they are growing the pure electric vehicles. remember, they have cost advantages because of their size and scale and chinese automakers also have the number of inherent advantages as they have grown the businesses with government support in china. >> question, we know about the relative price difference between the byd and the tesla. what do we know about the relative performance and or reliability of those cars? the pyds? >> reporter: byd's are fairly well regarded in terms of their reliability and their range. now, having said that, tyler, a lot of people in the u.s. will say well, i haven't seen a byd in the u.s.. they like to eventually sell in the u.s., but right now if you build a vehicle in china and

export to the u.s., there is a 25% tariff that gets added on. that is why you're not seeing pyds and the u.s. yet. however, byd is likely going to start manufacturing in mexico, at some point in the next four or five years. we have not seen them announce officially where the manufacturing facility will be, but they're looking at it. when that happens, that gives them entry into the u.s. through the north american free trade agreement. status really when the direct competition, aside from what we see in china where byd and tesla do compete vigorously, but in terms of in the united states, that's where you see them go head to head. >> all right, phil, thank you very much. phil reporting from santiago, chile. all right, stay classy, santiago. still to come, check out shares of pfizer. the company holding its oncology innovation day. with today also being national radices day, health care this hour, let's take a look at the different ways investors can play in the space including

gene at pharmaceutical company 'lta tthceisr. wel lko e o when we are back.

oh no, a rash. maybe it'll go away. awww, how am i going to find a doctor i'll actually like? is that a qr code? dr. stafford makes you feel at ease. thanks rash! you've got more options than you know. book now. your record label is taking off. but so is your sound engineer. you need to hire. i need indeed. indeed you do. indeed instant match instantly delivers quality candidates matching your job description. visit indeed.com/hire

my name is sister monica claire. because of tiktok, i've created a community where people can feel safe asking questions about spirituality. i try to provide a really accessible way of them learning about religion and spirituality, that's not intimidating. somebody in the comments said, i have no idea how i got on nun talk, but i'm not mad about it. i'm going to teach you how to pray. i'm going to teach you how to meditate, how to connect with a higher power, because we need that. we need strength and comfort. welcome back to power lunch.

with your cnbc news update. as expected, donald trump has appealed the wednesday night ruling qualifying him from the illinois republican primary ballot. the judge said the former president should be removed from the vote, for his role in the january 6th insurrection at the capital. mr. trump's team called the move unconstitutional. a recently introduced bill to protect in vitro fertilization in the state of alabama just passed with a commanding majority in the states house. now heads to the alabama senate for consideration. lawmakers are responding to an outcry across the state and the country, following the alabama supreme court's decision to define frozen embryos as children. several fertility clinics pause there ivf programs over legal fears in that state. hundreds of items belonging to sir elton john sold for more than double their estimated value at auction.

rocketing to $20 million. among the items up for grabs, a grand piano used by the rocket man, his prized classic bentley, and a leopard print rolex daytona, which is encrusted with 36 orange sapphires, you can't see it there yet, but for doesn't diamonds. there it is. that is one fancy time pace. back to you. >> reporter: a lot of blame going on there. thank you very much, bertha. >> reporter: still to come, our coverage of an issue that affects millions of americans, we are diseases. it sounds kind of like an oxymoron. but we will explain it when we speak to influential names in the treatment space. that is next. as we head to break, a quick power check on the positive side. for now, up 13% in earnings. on the negative side, excel energy, lower after a law firm alleged it is linked to the texas wildfires. we will be right back.

from pep in their step to shine in their coats, when people switch their dog's food to the farmer's dog, the effects can seem like magic. but there's no magic involved. (dog bark) it's just smarter, healthier pet food. it's amazing what real food can do. hey you, with the small business... ...whoa...

you've got all kinds of bright ideas, that your customers need to know about. constant contact makes it easy. with everything from managing your social posts, and events, to email and sms marketing. constant contact delivers all the tools you need to help your business grow. get started today at constantcontact.com constant contact. helping the small stand tall.

welcome back to power lunch. today is a leap day and also national rear disease day. a day to bring awareness to rare diseases and many people

and families affected by them. joining us now, some president and ceo of the national organization of rare disorders. also known as no word. here on set with, us are former fda commissioner and cnbc contributor. peter, let's begin with you. what is a rare disease? how do you define it? >> a radices in the united states is a population of patients under 200,000. that is the driver for the drug -- >> if you put all those diseases with 200,000 or a fewer cases combined, how many people are you talking about in the aggregate? >> we say 7000 reared diseases and about 30 million people in america, one in ten americans are impacted by a rare disease. so it's a significant number. >> reporter: so rare diseases are prevalent than. they may be rare but in some they are quite prevalent. >> that is correct.

that is correct. i would say, tyler, that you know, the important thing here is that, the 7000 rare diseases, the 30 million americans, 95% of them don't have an authorized or approved fda therapy. so that is a real challenge. we have 95% of the population who don't have a therapy. >> how costly are these diseases in the aggregate? number one? and number two, are they normally life-threatening, life limiting or are they chronic and manageable in that sense? >> well, i'm not a physician, so i will only answer part of the question. i will tell you that they are economically a burden on the economy and the country because the issue of being misdiagnosed happens to patients continuously. most of our patients it takes 45 years to get diagnosed. so there is a lot of health care costs that go into that before there is even a therapy developed. so it's an expensive and

timely, complicated issue for patients. >> reporter: scott, our grid aziz is increasing? it feels like i'm hearing about them more. maybe just the awareness of such as what we're hearing about. >> i think it's awareness, it's also that more rare diseases are addressable now. now we're talking about them. you know, no word has been instrumental in getting incentives for companies to try to develop drugs for these diseases. including the -- that implemented initially. also sustaining it. i think we're in an environment where it's more difficult to get policy to confer incentives for the development of some therapies for these red diseases. what we're looking at is super orphan diseases. diseases that can affect thousands, sometimes hundreds of patients. you now have the modalities to treat these diseases. the economic incentives are not always there though, and there are high prices that are charged with these drugs, it's an economical to develop therapeutics for these indications. we do not have the same policy solutions for these challenges that we had years ago because you don't have the same consensus in policy circles. particularly diseases where you

have a common phenom type. so, if the patient has a common experience, there might be a different genetic variation for different individual patients. you now have platforms like as a rna, or the nuclei, you could change the drug for each individual patient to attack these diseases. those are the places where it's hard, not only to get the infant centipede in place, but even the regulatory path for some of these potential cures. >> so how do you -- you're on the board of pfizer, right? how do you incentivize a large pharmaceutical company to try to develop a drug for one of these rare diseases when they know that it may be 150 people in the united states who might take it? >> the challenge for a baker drugmaker, getting into some of these spaces, you know, you look at some of these drugs, you're talking about hundreds of patients that might suffer from a condition. the political backlash of charging the prices you need to sustain the investment and get a return on the investment is very hard to do inside a big drugmaker because they are more prone to getting the political

-- over the high prices. so this is the domain of smaller companies, which i think have more latitude to charge those prices. so you've seen in recent years, large companies get out of these orphan spaces. it does worry me. you see capital coming out. i'm talking particularly about the super rare diseases, where there is still a market failure. and you know, it's hard to do second market innovation for these >> after a therapy comes to market, and you treat everyone with an inherited condition, the number of patients that will be newly diagnosed each year with that condition is not enough to sustain someone else coming into that space. some of these categories remained monopolies in perpetuity because you just cannot incentivize second market innovation that would bring down prices. >> reporter: let me ask you a question about the relative -- regulatory environment. peter, or come back to you in a moment. i'm guessing that the regulatory regime is set up two test drugs for the broadest effect, efficacy and safety. for the broadest number of

people. and here you have, by definition, conditions where there may be 150, 200, 500 people in the nited states, how do you test drugs in such a small sample set? >> look, it's very hard. and that is why, when i was there, the fda has tried to build natural history models where you can randomize against the natural history of patients with it condition. you don't have to randomized placebo. when you talk about these modalities where you individualize a treatment for patients based on their unique genetic profile, where they have a comment phenotypic, every patient might have a small difference in the genetic variation that drives the disease. so you might have to deliver, tweak the drug for each individual patient. that's very hard because the regulatory model tries to incentivize standardization of treatments, not the variation for each individual patient. that is why we need, i, think novel thinking about the regulatory path. >> reporter: peter, i read that 80% of rare diseases are

genetically based. does that provide us, now that we are mapping genes and have technologies like crispr and others, we can target genetic malformations or whatever they are, we could target them, is that a point of promise for the treatment every diseases? if so, how big a point of promise is that? >> again, scott was just saying about how -- i think the genetic issue for us really is the future of -- what we're seeing now, more and more, the opportunity for people to be able to get something, basically just for them, if you will. it's creates the problem we were just talking about, which is much smaller populations. there is not a policy or regulatory form right now that allows us to be able to do that effectively. i think that, while the future is there, there's a lot of work that needs to be done on a regulatory front to be able to make sure that we can get drugs approved and then pay for them.

>> if i have a small population and i take the drug so it works only for you, or essentially only for you, then you become, in a way, the test case for the drug, right? you become the guinea pig. >> exactly right. >> yes, these diseases, -- that's what you might be referring to, the n f one, it might not be enough of -- an f one but it might be a unique variation, what you need to have is a pathway that allows companies to study and aggregation of these patients, extrapolate beyond that other patients that have the common if you know type, the common syndrome, but maybe different genetic variations that might not have been included in the clinical trial. that's where the hiccup is right now. >> the system is not set up for that. >> no, and it's something that's been talked about literally for ten years now, how to create a viable regulatory model for this. that's where the real opportunity is for these superrich seizes, and a lot of them are inherited that children are born with. there's a compelling desire to try to get treatments.

notwithstanding the economic model, which i think also is a barrier to the investment in these spaces, the regulatory model does become also an impediment. >> wow. can i add to what scott just said because i think there's an important point, and that is that they're trying to find those patients as well. one of the things we've done in the last couple of years is develop a broad network called the -- weave now connected 41 of the top academic medical centers around the country and are connecting all of those the thing called nerds -- if they see something in a patient they can reach out to that network and ask other clinicians if they see something like that so we can start to bring what scott was just saying, some of the small populations, identify those people, bring them together. >> makes a lot of sense, informations sharing is paramount to solving these difficult problems. really important conversation. thank you so much, stick around we will have more to come. still ahead, we continue our special coverage of rare disease day with a few crispr

therapeutics ceo, samarth killarney joins us from --

[disconcerting stomach gurgle] not again. maybe i should get this looked at? [suggestive stomach gurgle] zocdoc? [talkative stomach gurgle] you're right, i bet they deal with this all the time. dr. finley really puts you at ease. let's do it! you've got more options than you know. book now. new projects means new project managers. you need to hire. i need indeed. indeed you do. when you sponsor a job, you immediately get your shortlist of quality candidates, whose resumes on indeed match your job criteria. visit indeed.com/hire and get started today. what is cirkul? cirkul is the fuel you need to take flight. cirkul is the energy that gets you to the next level. cirkul is what you hope for when life tosses lemons your way. cirkul, available at walmart and drinkcirkul.com.

ameritrade is now part of schwab. bringing you an elevated experience, tailor-made for trader minds. go deeper with thinkorswim: our award-wining trading platforms. unlock support from the schwab trade desk, our team of passionate traders who live and breathe trading. and sharpen your skills with an immersive online education crafted just for traders. all so you can trade brilliantly.

welcome back to power lunch, as we continue to mark rear disease day, let's take a closer look at companies trying to do good and do well with treatments for these diseases. let's look at cryptic pharmaceuticals, up 100 and 15% in a year. they spike in september, fairly straight up there, that was on positive news -- regarding a treatment of a rare hormone disorder. bridge biopharma has also tripled with a big frump -- last year -- positive results it a try or. we crispr therapeutics is another -- pretty big gains over the last year as well, up over 70% in a year. quoting us now is for samarth kulkarni, ceo of crispr

therapeutics. and doctor scott gottlieb, a cbc contributor who is still with us. let's say that dr. gottlieb was a partner at the venture firm enterprise associates which is a early investor in when crispr. thank you for being here, samarth we, obviously we had a fascinating conversation, i don't know if you heard all of it but it is about the hurdles to getting some of these drugs through when it comes to regulatory or otherwise being able to invest the money it takes to tackle these issues. where are we right now with your company? with crisper when it comes to tackling rare diseases? >> thank you for having me and it's great that you recognizing world rare disease day. in the last segment, the speaker was mentioning that there is 7000 reared diseases and what is disheartening is that 80 or 90% of those people will not have a good treatment available for those patients. and this is where technologies like crispr come in, we've had a great year, a great 12 months

because we have just had a drug approved for sickle cell disease, a more well-known rare disease, with our partner, vertex. so that is just the start. with the crisper technology, it is a programmable and scalable platform which connects to many bridges eases and provides transformative treatment for these where diseases. >> when it comes to what you're expecting going forward, what will we look forward to? give us good news on the horizon. is the research that is getting close to offer a new treatments for some of these individuals? >> yes, scott will attest that the science is moving at breakneck speed. it is not just crispr therapeutics but other companies in the space as well, doing work with rare diseases. we are working with a number of rare diseases, for instance, rare forms of cancer like t cell lymphoma's, type two diabetes, we are autoimmune diseases like lupus neuritis and also neuromuscular

diseases. the science is moving forward very quickly. the editing is working. we are able to take this crispr tool and apply it to specific locations on the genome and make a precise added to that fundamentally fixes the disease. so that's exciting to see. of course there is challenges, such as delivering it to the right organs. if you only want to add the liver or the brain, you know, we're trying to optimize the delivery solutions. but -- across all these therapeutic areas. >> back in 2000, -- therapeutics getting approved. they were usually used in third line treatments of cancer where there was no other available therapy. if you came to me at that point in time and said one day we will be able to use it to treat high cholesterol, i would look at you like crazy. there's so much complexity involved in those platforms.

they are being used in this rare -- as we get better vehicles to deliver with these, as we deliver the gene therapy, you will start to see these platforms migrate into more routine conditions and applications like regenerative medicine. we look at the profound impact, things like crispr therapeutics, they have sickle cell disease, thalassemia. i think you are going to see these kinds of platforms use in a wider range of diseases, not just radices's but more common illnesses as well. >> sam, i think i heard you basically say that in certain conditions, with certain gene editing, you can actually cure people. >> absolutely. we don't use that word cure lightly. in some cases the patients are symptom free for the rest of their lives, for instance. and why were able to do that is because we are going to the root of the disease. you heard from -- previously that 80% of the diseases have a

genetic base. with the whole genome sequencing project, we understand what causes the disease. what is the genetic that is resulting in the patients having a -- when you go to the root cause, at the genomic level, you potentially can cure the disease, or at least eliminate all symptoms for life. the other part of this is that, you know, when you talk about some of big pharma's not jumping to rare diseases because the market is not there, crispr is a scalable and programmable way of developing therapies which could make it much more efficient to develop drugs and returns eases because you're using the same -- but changing the zip code of where the genome is you are making the change. if you have a -- if that allows you to use the modular approach, you could develop drugs in a much more efficient fashion that would allow you to make the business case and develop it. even for ultra rare diseases,

you could deliver shareholder value. >> reporter: how hard is, it when you're dealing with radices is, how hard is it to get a treatment approved because the population is so small? if you see what i'm saying. in other words, you don't have thousands of people on whom you can test your medicine or your treatment. >> yes, it's challenging if you have to do a randomized controlled trial. you know, when scott was commissioner, you add attested to it, which is a novel form of thinking about developing drugs. one is using natural history. if you have a population that you know is declining in a certain way, and it's predictable because of the disease, and you administer your medicine and the decline doesn't happen, then you have a built in control for a clinical trial so you don't have to do a randomized control. the second is, in many cases of patients themselves, they are the control arm. in our sickle cell trial, we had patients coming in with over three or four hospitalizations per year, they would end up an ar before they go to therapy.

after they go to therapy, they had no more hospitalizations in most cases. similarly, they would require two units of blood every month and then after the transfusion, the therapy, they don't need any more transfusions. these are not always thinking about developing drugs that we don't have in the past. >> reporter: sam, if we can, before we let you go, this is the nbc after all, so we started at the segment talking about the investment case here. again, as we've reiterated over and over again, these drugs, researching them, deploying them, it's very very expensive. can you make the investment case for why it makes sense for us to do this from a financial and economic perspective? of course, we know it is for the good of the human race, of course. but from an economic and financial perspective, can you tell us why this is a good investment? >> absolutely. and where redoubling our efforts at crispr therapeutics for one -- to reasons. one is that with the platform of crispr, you take a

deterministic approach, less failures and less attrition in the drugs are developing. second, as i said, it's modular programmable. if you develop the platform that you just have to replace the genetic one for each disease. what it does is reduce the cost of development. and many cases, for big pharma, it cost two billion dollars to develop a drug. you can do it for much less if the regulatory environment is changing it allows for this. in which case, even if it's a small market, you can still make a positive return. then you have not just the possibility of return on one asset, but tons of diseases that you concur with a platform like crispr. >> so fascinating, samarth kulkarni, i thanks for joining us. dr. scott gottlieb is here and sticking around. coming up, shares of novo nordisk are up 70% over the last year. ozempic demand soaring. do me a favor, we celebrate black heritage, here's m&t bank

ceo, reni■jones, sharing his story. >> as a black ceo of a fortune 500 company, and maybe an exception, but it's important to remember that there are many exceptional people who inspire others every day. black heritage munch gives us the opportunity to celebrate many exceptional, for extraordinary people in our black and brown communities across north america. [sfx: wind, rain and rolling thunder] nobody's born with grit. british announcer: rose is really struggling. it's something you build over time. american announcer: that's 21 missed cuts in a row.

[car trunk slammed shut] for 88 years, morgan stanley has offered clients determination and forward thinking to create the future... crowd: stop it! ...only you can see. american announcer: rose, back in the winner's circle. [crowd cheers] [music out] this thing, it's making me get an ice bath again. what do you mean? these straps are mind-blowing! they collect hundreds of data points like hrv and rem sleep, so you know all you need for recovery. and you are? i'm an investor...in invesco qqq, a fund that gives me access to... nasdaq 100 innovations like... wearable training optimization tech. uh, how long are you... i'm done. i'm okay. i am every opponent you've ever faced. let's dance lizard. i can take any form i desire. awesome! i mean it's disturbing, but it's awesome.

democrats agree. conservative republican steve garvey is the wrong choice for the senate. ...our republican opponent here on this stage has voted for donald trump twice. mr. garvey, you voted for him twice... as your own man, what is your decision? garvey is wrong for california. but garvey's surging in the polls. fox news says garvey would be a boost to republican control of the senate. stop garvey.

adam schiff for senate. i'm adam schiff, and i approve this message. >> the weekly injections need a lifetime commitment, for faith and in her parents, they were worth a shot. >> would you give yourself a shot? >> my stomach. >> you hear the click? >> can you tell me what you are on? >> i have been on the jar is -- those epics since july. >> he switches and goes between ozempic. >> they are all in a class of drugs called glp-1 receptor agonists which mimic hormones.

>> what it does is it helps the body regulate insulin and glucose for blood sugar, it also helps the stomach feel full faster and longer. it also affects appetites in the brain, people have less of a drive to eat, it helps with what we have come to call for the noise. >> that was a click -- clip from bigshot, the ozempic revolution premieres at 10:00 p.m. eastern. drugs like ozempic and mounjaro have changed the way society approaches weight loss, we have a former pfizer board member who was featured in the documentary and is still with us. how big are these drugs likely to be, they are not only finding they are effective against weight gain, or bringing on weight loss.

a whole host of other conditions, potentially even including dementia. >> these will be a profound medical advance, where you were going to change the trajectory of morbidity and mortality, we think about this is a battle of what is the best drug, it will become the best label, which one ends up getting the best label to trying to approve the secondary gains. this is an important year, we saw select data, we ran a beta trial looking at a substantial reduction in cardiovascular risk in patients who previously had heart attack or stroke, they are now looking at data, they will probably approve a change the label to demonstrate cardiovascular risk reduction, lily will also have important data with their drug this year looking at reduction in that instance of sleep apnea or heart failure. collectively between nearly -- they have more than 15 trials that are registration quality trials, looking at things like

reducing the instance of fatty liver disease, dementia, if we continue to show the secondary benefits of weight reduction at these drugs achieve, and get that information to label, it will make these drugs compelling and hard for insurers not to pay for if you have that magnitude of public health. >> that would be my question, is this going to make them harder for insurers not to cover? ultimately, would it bring down the cost? >> is going to make it impossible for insurers not to pay, if you have a drug where you have a cohort of patients with significant cardiovascular disease that i've had stroke or heart attack, you can achieve 20% reduction, these are patients who have been maximally treated with hypertension medication, that is such a profound benefit, the benefit we have seen early as well, you do not leave the patients on the drug for a year, you saw it in the first months, that is so profound and will achieve so much savings for the health system overall

they will leap in, the productivity gains as people lose a profound amount of weight who are obese, they will perform better at work, they will have less joint disease, fewer days missed from illness or -- whatever. >> they data will get into drug labels, the one thing that will happen is both lily and novo, other companies have drugs in development, both acting on -- they will have data in 2025, lily has a drug which is called triple agonist, these look better than second and third generation iterations, we are in the early innings of innovation in the space. >> this is fascinating, i cannot wait to see -- tonight, 10:00 p.m. eastern time, thank you so much, dr. scott gottlieb. will be right back.

power e*trade's award-winning trading app makes trading easier. with its customizable options chain, easy-to-use tools and paper trading to help sharpen your skills, you can stay on top of the market from wherever you are. e*trade from morgan stanley power e*trade's easy-to-use tools make complex trading less complicated. custom scans help you find new trading opportunities, while an earnings tool helps you plan your trades and stay on top of the market. e*trade from morgan stanley

♪♪ ♪♪ ♪♪ ♪♪ ♪♪

businesses go further with 5g solutions. that's why they choose t-mobile for business. pga of america and t-mobile are partnering on 5g-powered analytics to help improve player performance. t-mobile's network helps aaa stay connected nationwide... to get their members back on the road. and las vegas grand prix chose t-mobile to help fuel operations for one of the world's largest racing events. now is the time to see what america's largest 5g network can do for your business.

what a wonderful hour it has been, let's bring you up to date on the dow, 007 james bond numbers down 26 at this hour, the nasdaq and s&p in the green. thanks for watching the special promo. closing bell starts right now. welcome back, i am scott walker at the u.s. stock exchange, we begin with a rally is another big month comes to a close, a month where stocks have broadened and hardened. we will ask our experts what it means for your money in the weeks ahead, take a look at your scorecard with 60 minutes to go in regulation, it is the final trading day, no big surprises from that pce report and that is helping tech and small-cap stocks which are more sensitive to moves and interest rates,